Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.02425 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Jonathan W Friedberg. Beteiligte Einrichtung: Wilmot Cancer Institute, Rochester, NY. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 1 Literaturangaben.
Abstract (Originalsprache)
Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES JCO Flashback: Evaluating Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed B-cell Lymphoma (1998). January 05, 2023 Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. January 05, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02425 Journal of Clinical Oncology - published online before print January 5, 2023 PMID: 36603540 Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy Jonathan W. Friedberg, MD, MMSc1,2,3xJonathan W. FriedbergSearch for articles by this author Show More 1Wilmot Cancer Institute, Rochester, NY2University of Rochester, Rochester, NY3Editor-in-Chief, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02425 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 1998, McLaughlin et al1 demonstrated that nearly half of patients with relapsed and refractory indolent B-cell lymphoma responded to single-agent anti-CD20 monoclonal antibody treatment with rituximab, with a median progression-free survival exceeding 12 months. The impact of this trial on patients with B-cell lymphomas cannot be overstated, as it directly led to the first US Food and Drug administration (FDA) approval of an oncologic monoclonal antibody and the development of subsequent studies resulting in major improvements in outcomes across a broad spectrum of B-cell–mediated diseases.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody TherapyThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jonathan W. FriedbergThis author is the Editor-in-Chief of Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Research Funding: Enterome (Inst)Patents, Royalties, Other Intellectual Property: Patient on bone marrow microenvironment signalsNo other potential conflicts of interest were reported. Companion JCO Flashback: Evaluating Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed B-cell Lymphoma (1998) Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Wilmot Cancer Institute, Rochester, NY.
- University of Rochester, Rochester, NY.
- Editor-in-Chief, Journal of Clinical Oncology, Alexandria, VA.
Zitieren
APA
Friedberg, J. W. (2023). Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02425
Vancouver
Friedberg JW. Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.02425
BibTeX
@article{Friedberg2023,
author = {Friedberg, Jonathan W},
title = {Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.02425}
}
EUVIMED